Jan Delabie
Papers
1
Total Citations
57
H-Index
1
About
Jan Delabie is a leading hematopathologist whose research has significantly advanced the understanding of B-cell lymphomas, particularly splenic marginal zone lymphoma (SMZL). His seminal work on the molecular pathogenesis of SMZL revealed the constitutive expression of AP-1 transcription factors—including c-jun, junD, junB, and c-fos—alongside the marginal zone B-cell transcription factor Notch2, providing critical insights into the unique signaling pathways driving this disease. This foundational study, cited over 57 times, has shaped diagnostic criteria and therapeutic targets for SMZL. Delabie’s broader contributions encompass the classification and molecular characterization of lymphoid malignancies, with his research consistently bridging histopathology and molecular biology to refine lymphoma subtyping. His work has been instrumental in identifying key biomarkers and genetic alterations that distinguish indolent from aggressive lymphomas, directly impacting clinical decision-making. With a career marked by high-impact publications and collaborations, Delabie remains a pivotal figure in hematopathology, guiding both diagnostic precision and the development of targeted therapies for patients with B-cell neoplasms.
Research Focus
Key Achievements
Top Papers
- 1